Eneida Mioshi

Eneida Mioshi

Auto-generated profile, based on publicly available information

Eneida Mioshi

School of Health Sciences, University of East Anglia

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2006 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
EMEneida Mioshi
Eneida Mioshi
KDKate Dawson
Kate Dawson
JMJoanna Mitchell
Joanna Mitchell
RARobert Arnold
Robert Arnold
JHJohn R. Hodges
John R. Hodges

5 January 2017 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
MSMichael Strong
Michael Strong
SASharon Abrahams
Sharon Abrahams
LGLaura H. Goldstein
Laura H. Goldstein
SWSusan Woolley
Susan Woolley
PMPaula Mclaughlin
Paula Mclaughlin
MTMartin R. Turner
Martin R. Turner
This article presents the revised consensus criteria for the diagnosis of frontotemporal dysfunction in amyotrophic lateral sclerosis (ALS) based on an international research workshop on frontotemporal dementia (FTD) and ALS held in London, Canada in June 2015. Since the publication of the Strong criteria, there have been considerable advances in the understanding of the neuropsychological profile of patients with ALS. Not only is the breadth and depth of neuropsychological findings broader than previously recognised – – including deficits in social cognition and language – but mixed deficits may also occur. Evidence now shows that the neuropsychological deficits in ALS are extremely heterogeneous, affecting over 50% of persons with ALS. When present, these deficits significantly and adversely impact patient survival. It is the recognition of this clinical heterogeneity in association with neuroimaging, genetic and neuropathological advances that has led to the current re-conceptualisation that neuropsychological deficits in ALS fall along a spectrum. These revised consensus criteria expand upon those of 2009 and embrace the concept of the frontotemporal spectrum disorder of ALS (ALS-FTSD).

15 August 2013 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Closed access
PDF file
SHSharpley Hsieh
Sharpley Hsieh
SSSamantha Schubert
Samantha Schubert
CHChristopher Hoon
Christopher Hoon
EMEneida Mioshi
Eneida Mioshi
JHJohn R. Hodges
John R. Hodges
Background/Aims: The aims of this study were to validate the newly developed version of the Addenbrooke's Cognitive Examination (ACE-III) against standardised neuropsychological tests and its predecessor (ACE-R) in early dementia. Methods: A total of 61 patients with dementia (frontotemporal dementia, FTD, n = 33, and Alzheimer's disease, AD, n = 28) and 25 controls were included in the study. Results: ACE-III cognitive domains correlated significantly with standardised neuropsychological tests used in the assessment of attention, language, verbal memory and visuospatial function. The ACE-III also compared very favourably with its predecessor, the ACE-R, with similar levels of sensitivity and specificity. Conclusion: The results of this study provide objective validation of the ACE-III as a screening tool for cognitive deficits in FTD and AD.

1 February 2011 in The Lancet Neurology
Verified
Journal Article
Closed access
OPOlivier Piguet
Olivier Piguet
MHMichael Hornberger
Michael Hornberger
EMEneida Mioshi
Eneida Mioshi
JHJohn R Hodges
John R Hodges

18 May 2010 in Neurology
Verified
Journal Article
Closed access
PDF file
EME. Mioshi
E. Mioshi
SHS. Hsieh
S. Hsieh
SSSharon Savage
Sharon Savage
MHM. Hornberger
M. Hornberger
JHJ.R. Hodges
J.R. Hodges
Objective: We aimed to develop a novel tool capable of staging disease severity in frontotemporal dementia (FTD) based upon functional dependence and behavioral changes, and to assess change over time in the 3 main FTD variants (behavioral variant FTD [bvFTD]; progressive nonfluent aphasia [PNFA]; and semantic dementia [SemD]). Methods: The Frontotemporal Dementia Rating Scale (FRS) was developed in a validation cohort of 77 consecutive clinic attendees (bvFTD = 29; PNFA = 20; SemD = 28) and applied to an independent sample of 75 patients (bvFTD = 28; PNFA = 21; SemD = 26) to establish intergroup differences. Assessments from 42 patients followed up after 12 months were used to determine annual progression. Finally, a combined sample (n = 152) was used to determine length of symptoms in each severity category. Results: Six severity stages were identified and operationalized based upon a 30-item questionnaire (very mild to profound). The cross-sectional study revealed much greater levels of impairment in bvFTD than in the language variants, with limited correlation with general cognitive measures. Patients with SemD showed the closest association between length of symptoms and stage, taking, on average, 10 years to reach the severe stage. Patients with bvFTD appear to move most quickly between stages and patients with PNFA were intermediate. The FRS was capable of detecting functional deterioration in all 3 variants over 12 months. Conclusions: Disease progression differs across frontotemporal dementia (FTD) variants. Patients with behavioral variant FTD progress rapidly whereas those with semantic dementia progress more slowly. The Frontotemporal Dementia Rating Scale can aid in staging and determining disease progression. Length of symptoms and global cognitive assessments alone do not reflect disease severity and progression in FTD.

11 September 2014 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Open access
PDF file
SHSharpley Hsieh
Sharpley Hsieh
SMSarah McGrory
Sarah McGrory
FLFelicity Leslie
Felicity Leslie
KDKate Dawson
Kate Dawson
SASamrah Ahmed
Samrah Ahmed
JHJohn R. Hodges
John R. Hodges
Background/Aims: We developed and validated the Mini-Addenbrooke's Cognitive Examination (M-ACE) in dementia patients. Comparisons were also made with the Mini Mental State Examination (MMSE). Method: The M-ACE was developed using Mokken scaling analysis in 117 dementia patients [behavioural variant frontotemporal dementia (bvFTD), n = 25; primary progressive aphasia (PPA), n = 49; Alzheimer's disease (AD), n = 34; corticobasal syndrome (CBS), n = 9] and validated in an independent sample of 164 dementia patients (bvFTD, n = 23; PPA, n = 82; AD, n = 38; CBS, n = 21) and 78 controls, who also completed the MMSE. Results: The M-ACE consists of 5 items with a maximum score of 30. Two cut-offs were identified: (1) ≤25/30 has both high sensitivity and specificity, and (2) ≤21/30 is almost certainly a score to have come from a dementia patient regardless of the clinical setting. The M-ACE is more sensitive than the MMSE and is less likely to have ceiling effects. Conclusion: The M-ACE is a brief and sensitive cognitive screening tool for dementia. Two cut-offs (25 or 21) are recommended. © 2014 S. Karger AG, Basel